Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lead-in telbivudine with or without tenofovir intensification in HBeAg-positive chronic hepatitis B
2007-004845-14Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of telbivudine and tenofovir disoproxil fumarate in Chronic hepatitis B (CHB) (2 arms), sponsored by Novartis. Primary endpoint: HBV DNA non-detectability at week 52. Started Feb 2008; status: completed.
02
Drugs
telbivudinetenofovir disoproxil fumarate
03
Conditions
Chronic hepatitis B (CHB)
Beyond the preview
Go deeper on 2007-004845-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004845-14.